Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130484961> ?p ?o ?g. }
Showing items 1 to 50 of
50
with 100 items per page.
- W3130484961 endingPage "SP021" @default.
- W3130484961 startingPage "SP021" @default.
- W3130484961 abstract "Abstract Next-generation sequencing (NGS) of breast cancer is becoming increasingly integrated into clinical practice. The fast pace of advances coupled with the dizzying array of technologies and platforms challenges the oncologist to select the right test for each patient. The choice could depend on a host of factors including the accessibility of clinical trials, clinical scenario and sample type, and the interest in turning up improbable but profoundly useful findings. Here, I will review the various types of clinical NGS platforms—including tumor and circulating-tumor DNA—particularly highlighting the unique features of commercial platforms that are widely available. Performance characteristics differ by technology: amplification technologies can detect mutations with smaller specimens, whereas capture-based NGS platforms may perform better for detecting novel genomic alterations. Assays integrating RNA-based analysis may enhance detection of rare but impactful gene fusions, such as of FGFR1-3 and NTRK1-3. Some potentially actionable genomic alterations only emerge after therapy, and are detected only with repeat tumor biopsy or cell-free DNA. Some assays include parallel germline testing which can clearly distinguish inherited from somatic (tumor-specific) findings, but may offer logistical challenges. An ever expanding set of ‘genomic phenotypes’ may be captured in these updated assays, with their limitations, including tumor mutational burden, microsatellite instability and homologous recombination. Newer platforms are now including exome and whole-genome sequencing, which may require more tissue and offer research insights, but currently add little to directing clinical care. New technologies, such as long-read and single-cell platforms of the future, may elucidate genomic features that are undetectable with current bulk short-read platforms, and will enable new genomic biomarkers. Despite the differences in genomics platforms, practical matters such as reimbursement, ease of use, and turn-around-time will likely govern platform selection for most oncologists in the near future. Citation Format: M Burkard. Understanding current platforms [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr SP021." @default.
- W3130484961 created "2021-03-01" @default.
- W3130484961 creator A5050180604 @default.
- W3130484961 date "2021-02-15" @default.
- W3130484961 modified "2023-09-27" @default.
- W3130484961 title "Abstract SP021: Understanding current platforms" @default.
- W3130484961 doi "https://doi.org/10.1158/1538-7445.sabcs20-sp21" @default.
- W3130484961 hasPublicationYear "2021" @default.
- W3130484961 type Work @default.
- W3130484961 sameAs 3130484961 @default.
- W3130484961 citedByCount "0" @default.
- W3130484961 crossrefType "journal-article" @default.
- W3130484961 hasAuthorship W3130484961A5050180604 @default.
- W3130484961 hasConcept C104317684 @default.
- W3130484961 hasConcept C16671776 @default.
- W3130484961 hasConcept C501734568 @default.
- W3130484961 hasConcept C51679486 @default.
- W3130484961 hasConcept C54355233 @default.
- W3130484961 hasConcept C60644358 @default.
- W3130484961 hasConcept C70721500 @default.
- W3130484961 hasConcept C86803240 @default.
- W3130484961 hasConceptScore W3130484961C104317684 @default.
- W3130484961 hasConceptScore W3130484961C16671776 @default.
- W3130484961 hasConceptScore W3130484961C501734568 @default.
- W3130484961 hasConceptScore W3130484961C51679486 @default.
- W3130484961 hasConceptScore W3130484961C54355233 @default.
- W3130484961 hasConceptScore W3130484961C60644358 @default.
- W3130484961 hasConceptScore W3130484961C70721500 @default.
- W3130484961 hasConceptScore W3130484961C86803240 @default.
- W3130484961 hasIssue "4_Supplement" @default.
- W3130484961 hasLocation W31304849611 @default.
- W3130484961 hasOpenAccess W3130484961 @default.
- W3130484961 hasPrimaryLocation W31304849611 @default.
- W3130484961 hasRelatedWork W1539933040 @default.
- W3130484961 hasRelatedWork W194485177 @default.
- W3130484961 hasRelatedWork W1997483710 @default.
- W3130484961 hasRelatedWork W2054240869 @default.
- W3130484961 hasRelatedWork W2104595023 @default.
- W3130484961 hasRelatedWork W2797028868 @default.
- W3130484961 hasRelatedWork W2894247673 @default.
- W3130484961 hasRelatedWork W3006152679 @default.
- W3130484961 hasRelatedWork W3029015202 @default.
- W3130484961 hasRelatedWork W3031411603 @default.
- W3130484961 hasVolume "81" @default.
- W3130484961 isParatext "false" @default.
- W3130484961 isRetracted "false" @default.
- W3130484961 magId "3130484961" @default.
- W3130484961 workType "article" @default.